Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

45.5K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
45.5K
Viral Recombination00:57

Viral Recombination

23.2K
Cells are sometimes infected by more than one virus at once. When two viruses disassemble to expose their genomes for replication in the same cell, similar regions of their genomes can pair together and exchange sequences in a process called recombination. Alternatively, viruses with segmented genomes can swap segments in a process called reassortment.
23.2K
What are Viruses?00:50

What are Viruses?

113.0K
Overview
113.0K
Retroviruses02:33

Retroviruses

12.2K
Retroviruses and retrotransposons both insert copies of their genetic elements into the genome of the host cell. Thus, the viral genes are passed on when the host genome is replicated or translated. A typical retroviral DNA sequence contains 3-4 genes that encode the different proteins required for its structural assembly and function as a molecular parasite. This DNA is transcribed into a single mRNA, which is very similar in structure to conventional mRNAs, i.e., it is capped at the 5’...
12.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Deciphering the genetic control of immune cell function at single-cell resolution: Disease-Specific Cis-eQTLs analysis of COVID-19.

Immunogenetics·2026
Same author

Leveraging two novel droplet-based single-cell RNA Sequencing platforms: a comparative study with 10x genomics.

BMC genomics·2025
Same author

[Hypoglycemic and hypocholesterolemic activities in vivo of polyphenols - popular components of dietary supplements].

Voprosy pitaniia·2025
Same author

Spectral Flow Cytometry: The Current State and Future of the Technology.

International journal of molecular sciences·2025
Same author

Experimental Animal Models of Phenylketonuria: Pros and Cons.

International journal of molecular sciences·2025
Same author

Heterologous Production of Antimicrobial Peptides in Yeast Allows for Massive Assessment of the Activity of DNA-Encoded Antimicrobials In Situ.

Acta naturae·2025

Related Experiment Video

Updated: May 23, 2025

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
09:29

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Published on: October 29, 2015

30.1K

Antivirotics based on defective interfering particles: emerging concepts and challenges.

S V Maryanchik1, S E Borovikova2, A O Ivanova3

  • 1Institute of Translational Medicine, Pirogov Russian National Research Medical University, Moscow, Russia.

Frontiers in Cellular and Infection Microbiology
|March 11, 2025
PubMed
Summary

Defective interfering particles (DIPs) naturally inhibit viral replication by competing for resources. This research explores DIP biology and their potential as a novel antiviral therapy against viral infections.

Keywords:
Nipah virusSARS-CoV-2antiviral therapycoxsackievirusdefective interfering particlespoliovirusviruses

More Related Videos

Assembly and Purification of Prototype Foamy Virus Intasomes
10:20

Assembly and Purification of Prototype Foamy Virus Intasomes

Published on: March 19, 2018

5.4K
Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle VLP-Based Vaccines Using a Capture Assay
05:15

Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle VLP-Based Vaccines Using a Capture Assay

Published on: February 10, 2022

3.5K

Related Experiment Videos

Last Updated: May 23, 2025

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
09:29

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Published on: October 29, 2015

30.1K
Assembly and Purification of Prototype Foamy Virus Intasomes
10:20

Assembly and Purification of Prototype Foamy Virus Intasomes

Published on: March 19, 2018

5.4K
Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle VLP-Based Vaccines Using a Capture Assay
05:15

Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle VLP-Based Vaccines Using a Capture Assay

Published on: February 10, 2022

3.5K

Area of Science:

  • Virology
  • Molecular Biology
  • Biotechnology

Background:

  • Viruses are obligate intracellular parasites, utilizing host cell machinery for replication.
  • Targeting viral replication is challenging due to the reliance on host systems, risking cellular toxicity.
  • Defective interfering particles (DIPs) are naturally occurring viral mutants that interfere with standard viral replication.

Purpose of the Study:

  • To elucidate the fundamental biology of Defective Interfering Particles (DIPs).
  • To review advancements in Defective Interfering Particle (DIP)-based antiviral technologies.
  • To analyze the therapeutic potential of DIPs and survey current antiviral strategies.

Main Methods:

  • Literature review of Defective Interfering Particle (DIP) biology and antiviral applications.
  • Analysis of existing preventive and therapeutic antiviral strategies.
  • Synthesis of current research on DIPs for novel antiviral development.

Main Results:

  • Defective Interfering Particles (DIPs) emerge during viral infections and possess inherent antiviral properties.
  • DIPs compete with standard viruses for essential replication resources, thereby inhibiting viral spread.
  • Advances in DIP technology show promise for developing targeted antiviral therapies.

Conclusions:

  • Defective Interfering Particles (DIPs) represent a promising platform for novel antiviral therapies.
  • DIP-based strategies offer a potential alternative to traditional antivirals with reduced host cell toxicity.
  • Further research into DIPs can lead to innovative approaches for managing viral infections.